Effect of GM1 ganglioside treatment on postlesion responses of cholinergic enzymes in rat hippocampus after various partial deafferentations

Abstract

The effect of intramuscular administration of monosialoganglioside (GM1) on postlesion responses of choline acetyltransferase and acetylcholinesterase activity in partially deafferented rat hippocampus was studied at various survival times. Lesions partially destroying the medioventral, septal area, or lesions performed in supracallosal stria including corpus callosum and cingulum evoked cholinergic denervation of the hippocampus, while those made in entorhinal cortex resulted in partial glutamatergic deafferentation. GM1 treatment potentiates the responses of both cholinergic enzymes, independently of whether the partial deafferentation was homo- or heterotypical. These data indicate that GM1 may facilitate the regrowth of new cholinergic nerve terminals. However, an effect on other compensatory processes, especially in the first postoperative period, is also possible.

Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins

“…Experimental evidence has shown that gangliosides facilitate cholinergic reinnervation after lesions of the septal nuclei or of the nucleus basalis, or after transection of the fimbria-fornix [34][35][36][37][38]. In addition, GM1 exhibited neuroprotection and promoted reinnervation of cholinergic neurons after cortical infarction, which produces well-defined anatomical and biochemical deficits of the nucleus basalis in rats as well as nonhuman primates [39][40][41][42]. Remarkably, GM1 can also promote morphological and functional recovery in normal aged animals.…”

Ganglioside GM1 attenuates scopolamine-induced amnesia in rats and mice

“…In this context, although the exact mechanism by which GM1 ganglioside modifies cholinergic function in young and old rats is still under investigation, there is a considerable number of evidence suggesting that GM1 effects could be cholinergic in nature. It has been verified, for example, that IM administration of gangliosides potentiated post-lesion response of choline acetyltransferase and acetylcholinesterase in rat hippocampus after medioventral and septal lesions (Wojcik et al 1982;Oderfeld-Nowak et al 1984). In addition, GM1 treatment was able to increase cortical acetylcholine release in vivo in rats with unilateral decortication (Maysinger et al 1988(Maysinger et al , 1990.…”

GM1 ganglioside in Parkinson's disease: Results of a five year open study

“…GM1 ganglioside is a normal constituent of nerve cell membranes, is known to modulate a number of cell surface and receptor activities and plays important roles in neuronal differentiation and development [6], protein phosphorylation [7], and synaptic function [8]. Treatment with GM1 following a number of different types of central nervous system lesions in experimental animals [9][10][11][12][13][14] has resulted in significant biochemical and behavioral recovery and pretreatment with GM1 inhibits damage resulting from a variety of neurotoxic exposures [15][16][17]. GM1 administration has been effective in ameliorating neurochemical and behavioral alterations in murine and non-human primate models of PD [13,[18][19][20].…”